H&T Presspart is a leading developer and manufacturer of drug delivery devices and components. With more than 50 years of experience, the company is recognized for its expertise, quality, and innovation across the pharmaceutical industry. Through a broad portfolio of components, device solutions, and services, H&T Presspart partners with customers to deliver exceptional experiences and accelerate the path to market for drug–device programs. Following the acquisition of Plas-Tech Engineering—continuing in the market under the Plas-Tech brand—H&T Presspart expands its capabilities with services and solutions tailored to the parenteral market, particularly small-batch and lower-volume needs. The acquisition also adds Plas-Tech’s Equinox portfolio of proprietary prefillable syringes engineered for advanced therapeutics, including biologics and high-viscosity formulations. Together, H&T Presspart and Plas-Tech Engineering provide end-to-end support from concept, prototyping, piloting and tooling through manufacturing at global scale, with sites in Germany, Spain, Switzerland, the USA, and the UK, and sales representation in China, India, and Uruguay.
Looking for a particular H&T Presspart employee's phone or email?
The H&T Presspart annual revenue was $31 million in 2026.
Thomas Portune is the Chairman - Managing Director of H&T Presspart.
254 people are employed at H&T Presspart.
The NAICS codes for H&T Presspart are [3254, 32, 32541, 325].
The SIC codes for H&T Presspart are [283, 28].